Syntekabio will present its AI drug discovery platforms, DeepMatcher® and NEO-ARS™, at the UKC on August 19, 2022. The event fosters collaboration between U.S. and Korean professionals, featuring networking opportunities and presentations on innovative technologies. Dr. Kilyoung Kim will represent Syntekabio, emphasizing the company’s commitment to advancing drug discovery through AI.
Syntekabio, a leading global AI-driven drug discovery and development firm, is set to unveil its advanced AI drug discovery platforms, DeepMatcher® and NEO-ARS™, at the US-Korea Conference (UKC) on August 19, 2022, in Arlington, Virginia. This event focuses on fostering collaboration between U.S. and Korean professionals across various fields, promoting networking opportunities among entrepreneurs and business leaders.
The conference will include the 4th Innovation and Entrepreneurship Symposium (IES), where companies can showcase their innovative products and technologies. Dr. Kilyoung Kim, Chief Scientific Officer and President of Syntekabio USA, will present the company’s latest advancements in the field of AI drug discovery during his session at 5 p.m. ET.
Syntekabio, founded in 2009 in South Korea, utilizes AI and big data to drive drug discovery and development efforts globally. The company aims to create transformative medicines compliant with international standards, thus improving health outcomes. Attendees and media representatives will have opportunities for one-on-one meetings with the Syntekabio leadership team following the presentation, ensuring comprehensive engagement and insightful discussions.
The article highlights the significant advancements in AI-based drug discovery showcased by Syntekabio at the US-Korea Conference (UKC). This conference serves as a platform for collaboration in science, engineering, and technology between the United States and South Korea. Syntekabio’s innovative products, such as DeepMatcher® and NEO-ARS™, exemplify the application of artificial intelligence in enhancing drug discovery processes.
In summary, Syntekabio is poised to impact the pharmaceutical industry with its AI-driven platforms, DeepMatcher® and NEO-ARS™, presented at the upcoming UKC symposium. The synergy between U.S. and Korean professionals at this event underscores the global nature of innovation in drug discovery, with potential for transformative health solutions emerging from these collaborations.
Original Source: www.globenewswire.com